Summary
Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritional
imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet
food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and
wellbeing.
The PetLife project is based on a promising market and growth opportunity deriving from our current L-Cysteine derivative
product line for use in plant nutrition. This latent cysteine is released into the plant gradually, providing its organism with
several essential health benefits that extend to animals as well. AXEB is set to be the first in Europe and globally to validate
and introduce L-cysteine derivatives as nutritional additives for animals, to solve the problem of providing cysteine without
causing nutritional imbalances and weight gain. The health benefits to be proved in phase 2 validation will convince pet
owners and feed manufacturers of the worth of these new added-value formulations.
Our objective is to take advantage of our know-how in order to broaden the use of this innovative compound as an animal
nutrient and access the EU pet food industry and European pet owners who spend up to €21,000 on each pet over its
lifetime, and €55 per pet every year on veterinary care.
When scaled up to industrial production, the proposed PetLife L-Cysteine derivatives will be commercialized with a target
price 25% cheaper than current pet food additives, and provide more long-ranging health benefits to reduce end user
veterinary expenses.
Although we already possess the knowledge in biotechnology processes for molecule synthesis, we require assistance to
enter the pet food market due to the rigorous regulatory approval process for new additives in the European market. The
possibility of European funding will help us cross the ‘valley of death’ from development to marketplace.
imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet
food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and
wellbeing.
The PetLife project is based on a promising market and growth opportunity deriving from our current L-Cysteine derivative
product line for use in plant nutrition. This latent cysteine is released into the plant gradually, providing its organism with
several essential health benefits that extend to animals as well. AXEB is set to be the first in Europe and globally to validate
and introduce L-cysteine derivatives as nutritional additives for animals, to solve the problem of providing cysteine without
causing nutritional imbalances and weight gain. The health benefits to be proved in phase 2 validation will convince pet
owners and feed manufacturers of the worth of these new added-value formulations.
Our objective is to take advantage of our know-how in order to broaden the use of this innovative compound as an animal
nutrient and access the EU pet food industry and European pet owners who spend up to €21,000 on each pet over its
lifetime, and €55 per pet every year on veterinary care.
When scaled up to industrial production, the proposed PetLife L-Cysteine derivatives will be commercialized with a target
price 25% cheaper than current pet food additives, and provide more long-ranging health benefits to reduce end user
veterinary expenses.
Although we already possess the knowledge in biotechnology processes for molecule synthesis, we require assistance to
enter the pet food market due to the rigorous regulatory approval process for new additives in the European market. The
possibility of European funding will help us cross the ‘valley of death’ from development to marketplace.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/717542 |
| Start date: | 01-03-2016 |
| End date: | 31-08-2016 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritionalimbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet
food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and
wellbeing.
The PetLife project is based on a promising market and growth opportunity deriving from our current L-Cysteine derivative
product line for use in plant nutrition. This latent cysteine is released into the plant gradually, providing its organism with
several essential health benefits that extend to animals as well. AXEB is set to be the first in Europe and globally to validate
and introduce L-cysteine derivatives as nutritional additives for animals, to solve the problem of providing cysteine without
causing nutritional imbalances and weight gain. The health benefits to be proved in phase 2 validation will convince pet
owners and feed manufacturers of the worth of these new added-value formulations.
Our objective is to take advantage of our know-how in order to broaden the use of this innovative compound as an animal
nutrient and access the EU pet food industry and European pet owners who spend up to €21,000 on each pet over its
lifetime, and €55 per pet every year on veterinary care.
When scaled up to industrial production, the proposed PetLife L-Cysteine derivatives will be commercialized with a target
price 25% cheaper than current pet food additives, and provide more long-ranging health benefits to reduce end user
veterinary expenses.
Although we already possess the knowledge in biotechnology processes for molecule synthesis, we require assistance to
enter the pet food market due to the rigorous regulatory approval process for new additives in the European market. The
possibility of European funding will help us cross the ‘valley of death’ from development to marketplace.
Status
CLOSEDCall topic
SC5-20-2015-1Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
